Marcos G. Diaz

Salamanca, CL, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.

Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.

Journal: Blood advances

Published: September 26, 2025

Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.

Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.

Journal: The Lancet. Oncology

Published: September 13, 2023

High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.

High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.

Journal: Haematologica

Published: August 20, 2018

The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia.

The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia.

Journal: Leukemia

Published: November 23, 2016

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.

Journal: Haematologica

Published: July 11, 2016

Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.

Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.

Journal: Cancer genetics

Published: October 08, 2012

DNA methylation dynamics in blood after hematopoietic cell transplant.

DNA methylation dynamics in blood after hematopoietic cell transplant.

Journal: PloS one

Published: September 17, 2012

Common infectious agents and monoclonal B-cell lymphocytosis: a cross-sectional epidemiological study among healthy adults.

Common infectious agents and monoclonal B-cell lymphocytosis: a cross-sectional epidemiological study among healthy adults.

Journal: PloS one

Published: July 19, 2012

Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma.

Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma.

Journal: European journal of haematology

Published: July 13, 2012

The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma.

The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma.

Journal: Annals of hematology

Published: May 17, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026